AGIO Shares Outstanding History
Below is a table of the AGIO shares outstanding history going back to 7/24/2013:

Date AGIO Shares Outstanding
7/24/201329.38M
9/1/201331.07M
11/1/201331.17M
3/14/201431.59M
8/6/201434.46M
11/6/201434.68M
2/20/201537.22M
5/8/201537.30M
8/5/201537.44M
11/4/201537.64M
2/23/201637.85M
5/5/201637.92M
8/5/201638.05M
10/31/201642.01M
2/14/201742.23M
5/1/201748.20M
8/4/201748.39M
10/30/201748.75M
2/9/201857.33M
4/30/201857.61M
7/30/201857.99M
10/29/201858.18M
2/8/201958.40M
4/26/201958.71M
7/26/201958.75M
8/14/20199.19M
10/25/201958.88M
2/13/202068.51M
4/24/202068.89M
7/24/202069.11M
10/30/202069.26M
2/18/202169.60M
4/23/202169.94M
7/23/202158.95M
10/29/202154.31M
2/18/202254.64M
4/29/202254.79M
7/29/202254.82M

Also see: AGIO Market Cap History
AGIO YTD Return
AGIO Historical Shares Outstanding:
+7.16% CAGR
AGIO Historical Shares Outstanding: +7.16% CAGR

Mouse over chart for data details
7/24/2013 ...7/29/2022
Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD. We show 38 historical shares outstanding datapoints in our coverage of AGIO's shares outstanding history.

Understanding the changing numbers of AGIO shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AGIO versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AGIO by allowing them to research AGIO shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree AGIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Agios Pharmaceuticals (AGIO) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AGL Shares Outstanding History
AGLE Shares Outstanding History
AGN Shares Outstanding History
AGRX Shares Outstanding History
AGTC Shares Outstanding History
AGTI Shares Outstanding History
AHCO Shares Outstanding History
AHPI Shares Outstanding History
AIKI Shares Outstanding History
AIMT Shares Outstanding History
More Healthcare companies »

 

AGIO Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.